Currently Viewing:
American College of Rheumatology Annual Meeting 2019 Highlights
2019 Brought Impressive Results for TNF Inhibitors, Research Into Monotherapy, Interest in CBD
November 10, 2019
Dr Yusuf Yazici Discusses Disease Activity Assessment Tools in RA, Osteoarthritis
November 11, 2019
Dr Daniel Clauw Highlights the Turn Toward Nondrug Therapies to Treat Chronic Pain
November 11, 2019
Using Patient Characteristics to Predict Clinical Outcomes in RA
November 11, 2019
Dr Jeffrey Curtis Discusses Using Live Virus Vaccines in Immunocompromised Patients
November 11, 2019
Currently Reading
Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested
November 12, 2019
Sarilumab Reduces Unacceptable Pain, Lowers Glucocorticoid Doses, and Costs Less per Responder Than Comparators
November 12, 2019
Dr Stephen Messier Discusses the Importance of Nonpharmacologic Interventions in Knee OA
November 13, 2019
Evaluating Sarilumab's Efficacy as a Monotherapy in Rheumatoid Arthritis
November 13, 2019
Using Technology and Virtual Reality to Improve Outcomes, Quality of Life
November 13, 2019
Sarilumab as a Combination or Monotherapy Successfully Targets IL-6, Improves Symptoms in Patients With RA
November 14, 2019
The Many Benefits of, and Barriers to, Exercise in Patients With Rheumatologic Diseases
November 14, 2019
Treating Pain in Rheumatologic Diseases With Opioids
November 14, 2019
PROs: Which Are Important to Patients and How Successfully Are They Integrated Into Clinical Care?
November 14, 2019

Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested

While biosimilars have brought down the cost of therapies, the savings are not quite as huge as providers may have been led to believe when biosimilars were initially under development, said Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic.


While biosimilars have brought down the cost of therapies, the savings are not quite as huge as providers may have been led to believe when biosimilars were initially under development, said Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic.

Transcript

In rheumatology, are biosimilars bringing down the cost of treatment for patients just yet?

So, I do think bringing down the cost of therapy is important. It has to be affordable—these patients are usually on it for long periods of time. This is a chronic illness, so we are dealing with the healthcare value-based system as a whole. I do think that biosimilars, in my mind, when they were first being developed, was that they would have huge cost savings. So, in my mind, huge cost savings is not 10%, 20%, 25%, which is what we’re seeing. To me, huge cost savings is at least slashing it down by half. Half price—50%, right? So, I’m not seeing that.

So, I do think that it’s not as cost saving as I had hoped. So, it’s a little bit of a letdown when I’m only seeing a small percentage decrease in biosimilars.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up